Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study

Am J Dig Dis. 1977 Jun;22(6):477-84. doi: 10.1007/BF01072499.

Abstract

In a prospective, randomized, double-blind study of prednisolone therapy of acute alcoholic hepatitis, 39% of the total group of 28 patients died. Mortality and cumulative survival were similar in steroid- and placebo-treated patients. After 14 days of therapy, the serum albumin concentration and white blood count were significantly higher in the steroid group, but all other parameters were similar. An increased risk of fungal infection appeared to be associated with steroid therapy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Adrenal Cortex Hormones / therapeutic use*
  • Alcoholism / complications*
  • Alkaline Phosphatase / blood
  • Aspartate Aminotransferases / blood
  • Bilirubin / blood
  • Clinical Trials as Topic
  • Connecticut
  • Double-Blind Method
  • Hepatic Encephalopathy / complications
  • Hepatitis / drug therapy*
  • Hepatitis / etiology
  • Hepatitis / mortality
  • Humans
  • Leukocyte Count
  • Liver Function Tests
  • Male
  • Middle Aged
  • Mycoses / complications
  • Placebos
  • Prednisolone / adverse effects
  • Prednisolone / therapeutic use
  • Prospective Studies
  • Serum Albumin / metabolism

Substances

  • Adrenal Cortex Hormones
  • Placebos
  • Serum Albumin
  • Prednisolone
  • Aspartate Aminotransferases
  • Alkaline Phosphatase
  • Bilirubin